• A year after ditching in-house neuroscience work, Pfizer execs shared their ‘star cluster' strategy for betting on promising brain drug startups

    3 days ago - By Business Insider

    Last year, after several failures related to Alzheimer's disease drugs, pharmaceutical giant Pfizer announced it was stepping away from neuroscience research and development.
    The company isn't completely done with the field. It partnered with Bain Capital in October to launch neuroscience spinoff Cerevel Therapeutics .
    Cerevel is part of a much larger strategy to maintain a presence in neuroscience, Pfizer Ventures executives explained in an interview with Business Insider during the J.P. Morgan Healthcare Conference .
    Nearly a year after throwing in the towel on a suite of efforts to...
    Read more ...